34 related articles for article (PubMed ID: 11287774)
1. Decipher the Immunopathological Mechanisms and Set Up Potential Therapeutic Strategies for Patients with Lupus Nephritis.
Tsai CY; Li KJ; Shen CY; Lu CH; Lee HT; Wu TH; Ng YY; Tsao YP; Hsieh SC; Yu CL
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373215
[TBL] [Abstract][Full Text] [Related]
2. Identification and Quantitation of Leukocyte Populations in Human Kidney Tissue by Multi-parameter Flow Cytometry.
Kildey K; Law BMP; Muczynski KA; Wilkinson R; Helen H; Kassianos AJ
Bio Protoc; 2018 Aug; 8(16):e2980. PubMed ID: 34395780
[TBL] [Abstract][Full Text] [Related]
3. Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
Cormican S; Griffin MD
Front Immunol; 2021; 12():664202. PubMed ID: 34163473
[TBL] [Abstract][Full Text] [Related]
4. FKN Facilitates HK-2 Cell EMT and Tubulointerstitial Lesions via the Wnt/β-Catenin Pathway in a Murine Model of Lupus Nephritis.
Fu D; Senouthai S; Wang J; You Y
Front Immunol; 2019; 10():784. PubMed ID: 31134047
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cells in Kidney Health and Disease.
Turner JE; Rickassel C; Healy H; Kassianos AJ
Front Immunol; 2019; 10():587. PubMed ID: 30972076
[TBL] [Abstract][Full Text] [Related]
6. Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease.
Yadav AK; Kumar V; Jha V
Indian J Nephrol; 2016; 26(4):275-9. PubMed ID: 27512300
[TBL] [Abstract][Full Text] [Related]
7. Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis.
Gokcan H; Yurtcu E; Selcuk H; Sahin FI
Bosn J Basic Med Sci; 2015 May; 15(2):73-7. PubMed ID: 26042517
[TBL] [Abstract][Full Text] [Related]
8. Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice.
Song KH; Park J; Park JH; Natarajan R; Ha H
Diabetologia; 2013 Jul; 56(7):1661-9. PubMed ID: 23604552
[TBL] [Abstract][Full Text] [Related]
9. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease.
Sans M; Danese S; de la Motte C; de Souza HS; Rivera-Reyes BM; West GA; Phillips M; Katz JA; Fiocchi C
Gastroenterology; 2007 Jan; 132(1):139-53. PubMed ID: 17241867
[TBL] [Abstract][Full Text] [Related]
10. Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.
Hasegawa M; Sato S; Echigo T; Hamaguchi Y; Yasui M; Takehara K
Ann Rheum Dis; 2005 Jan; 64(1):21-8. PubMed ID: 15608300
[TBL] [Abstract][Full Text] [Related]
11. Fractalkine (CX3CL1) and brain inflammation: Implications for HIV-1-associated dementia.
Cotter R; Williams C; Ryan L; Erichsen D; Lopez A; Peng H; Zheng J
J Neurovirol; 2002 Dec; 8(6):585-98. PubMed ID: 12476352
[TBL] [Abstract][Full Text] [Related]
12. Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion.
Chakravorty SJ; Cockwell P; Girdlestone J; Brooks CJ; Savage CO
Clin Exp Immunol; 2002 Jul; 129(1):150-9. PubMed ID: 12100035
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis.
Yoshimoto S; Nakatani K; Iwano M; Asai O; Samejima K; Sakan H; Terada M; Harada K; Akai Y; Shiiki H; Nose M; Saito Y
Am J Kidney Dis; 2007 Jul; 50(1):47-58. PubMed ID: 17591524
[TBL] [Abstract][Full Text] [Related]
14. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis.
Wada T; Furuichi K; Segawa-Takaeda C; Shimizu M; Sakai N; Takeda SI; Takasawa K; Kida H; Kobayashi KI; Mukaida N; Ohmoto Y; Matsushima K; Yokoyama H
Kidney Int; 1999 Sep; 56(3):995-1003. PubMed ID: 10469367
[TBL] [Abstract][Full Text] [Related]
15. Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases.
Furuichi K; Wada T; Sakai N; Iwata Y; Yoshimoto K; Shimizu M; Kobayashi K; Takasawa K; Kida H; Takeda SI; Mukaida N; Matsushima K; Yokoyama H
Am J Nephrol; 2000; 20(4):291-9. PubMed ID: 10970982
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine in vascular biology: from basic research to clinical disease.
Umehara H; Bloom ET; Okazaki T; Nagano Y; Yoshie O; Imai T
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):34-40. PubMed ID: 12969992
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine in rheumatoid arthritis and allied conditions.
Umehara H; Tanaka M; Sawaki T; Jin ZX; Huang CR; Dong L; Kawanami T; Karasawa H; Masaki Y; Fukushima T; Hirose Y; Okazaki T
Mod Rheumatol; 2006; 16(3):124-30. PubMed ID: 16767549
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of fractalkine in human crescentic glomerulonephritis.
Furuichi K; Wada T; Iwata Y; Sakai N; Yoshimoto K; Shimizu M; Kobayashi K; Takasawa K; Kida H; Takeda S; Matsushima K; Yokoyama H
Nephron; 2001 Apr; 87(4):314-20. PubMed ID: 11287774
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
